Nattokinase is one of the more interesting supplements to grade honestly, because unlike most “natural blood thinners” it starts from a real, well-characterized mechanism. It is a serine protease — a fibrin-cleaving enzyme — isolated in 1987 from natto, the sticky fermented-soybean dish, by a Japanese researcher who dropped it onto an artificial fibrin clot and watched the clot dissolve.[1] That single vivid observation is the seed of the entire modern “circulation and clot support” category. The honest question is not whether nattokinase does something in a dish — it clearly does — but whether swallowing it translates into meaningful, safe benefits in people. There the picture gets thinner and more cautious.
The mechanism is real: it cleaves fibrin
Fibrin is the protein mesh that holds a blood clot together; your body dissolves clots with its own enzyme, plasmin. Nattokinase is an outside enzyme that also directly degrades fibrin, and the original 1987 paper showed it doing exactly that on a standard fibrin plate, with a potency that made it stand out among fermented foods.[1] This is why nattokinase is not in the same category as most wishful “detox” supplements — there is a defined molecule with a defined enzymatic action. The catch is the one that haunts every oral enzyme: it is a large protein, and the stomach and gut are built to take proteins apart. Whether enough intact, active enzyme survives digestion and reaches the bloodstream to matter has always been the pivotal question, and it is the reason a compelling test-tube result cannot be assumed to carry over to a capsule.
It does reach the blood in an active-enough form — at least by markers
The best evidence that nattokinase is more than a lab curiosity comes from a controlled human study in which a single oral dose shifted fibrinolytic and anticoagulation markers — measures such as D-dimer and fibrin-degradation products rose and clotting factors moved — consistent with enhanced clot breakdown and reduced clotting tendency after ingestion.[2] That is a genuinely useful data point: it suggests the enzyme (or its downstream effects) does register systemically, which partly answers the absorption worry. But it is worth being precise about what this shows. These are biomarkers of the clotting system, not clinical events. Moving a coagulation marker is evidence of biological activity; it is not, by itself, evidence that you will have fewer strokes or heart attacks — and, as the safety section notes, the very same finding is the reason to respect its bleeding risk.
Blood pressure, plaque, and lipids: modest signals, small trials
On blood pressure the human data are actually reasonable for a supplement. A randomized, controlled trial found that nattokinase lowered systolic and diastolic blood pressure over eight weeks in people with elevated readings, a modest but statistically real effect.[3] On vascular disease, a clinical study reported that nattokinase was associated with reduced carotid-artery plaque size and improved lipid measures in patients with atherosclerosis and hyperlipidaemia,[4] and a much larger observational-style clinical study in over a thousand participants likewise linked it to slowed atherosclerosis progression and better lipids.[5] Taken together these are encouraging, directionally consistent signals across blood pressure, plaque, and lipids.
The honest caveats matter as much as the signals. These trials are small, relatively short, and several are industry-linked or run in single centers, the carotid and large-cohort studies are published in ways that are harder for outside readers to scrutinize, and crucially none measure hard cardiovascular outcomes — no trial has shown nattokinase reduces heart attacks, strokes, or deaths. There is also a useful cautionary result on lipids specifically: in one controlled trial, nattokinase on its own did not meaningfully improve blood lipids — the benefit only appeared when it was combined with red yeast rice (which contains a natural statin), meaning some of the “nattokinase lowers cholesterol” marketing is really crediting the wrong ingredient.[6]This is the same pattern seen across the supplement aisle, where a plausible mechanism and a few small trials get inflated into settled fact — the discipline we apply to CoQ10 and resveratrol applies here too.
The safety story: bleeding is the real caveat
With nattokinase the safety concern is not hypothetical hand-waving — it follows directly from the mechanism. An agent that promotes fibrinolysis and reduces clotting is, definitionally, pushing your hemostatic balance toward bleeding, and the human marker study confirms it moves those systems in exactly that direction.[2] That makes the highest-risk situations easy to name: combining it with prescription anticoagulants or antiplatelets (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel), taking it alongside other supplements with blood-thinning effects (fish oil, high-dose vitamin E, ginkgo), using it around surgery or dental procedures, or taking it with a bleeding disorder or a history of hemorrhagic stroke. In those settings nattokinase is not a gentle wellness add-on; it is a variable that can stack with a real drug. Reported adverse effects in trials are otherwise generally mild, but “well tolerated in small trials” is not the same as “safe to combine with your blood thinner,” and product potency is inconsistent because supplements are unstandardized.
Dose, and the honest bottom line
Nattokinase is dosed in fibrinolytic units (FU) rather than milligrams, and the human trials generally used roughly 2,000 FU per day (about 100 mg of a standardized preparation), the level used in the blood-pressure and vascular studies.[3] Because products vary widely in actual enzymatic activity, the FU figure on the label matters more than the milligram weight — and there is no basis for assuming “more is better,” since higher fibrinolytic activity is precisely what raises bleeding risk.
So where does that leave nattokinase? It is one of the few “natural blood thinner” supplements with a real, characterized enzymatic mechanism and a handful of small human trials pointing in a favorable direction on blood pressure, plaque, and clotting markers. That is genuinely more than most of the category can claim. But the evidence base is thin, often industry-linked, short-term, and devoid of hard cardiovascular-outcome data, and the same fibrinolytic action that makes it interesting is what makes it risky alongside anticoagulants or before surgery. Useful, plausibly, for the right person — but cautious is the correct posture. This is educational information about the state of the evidence, not medical advice; anyone on a blood thinner, facing a procedure, or with cardiovascular disease should treat nattokinase as a decision to make with a clinician, not a supplement to add quietly.